Abstract
Purpose: :
To study the in-vitro susceptibility profiles of ceftobiprole, a novel 5th generation cephalosporin against ocular isolates of Methicillin Resistant Staph aureus (MRSA).
Methods: :
15 MRSA, 3 Methicillin Sensitive Staph aureus (MSSA), 3 Staph epidermidis, 1 Strep viridans group, and 1 each of Serratia marcescens, Haemophilus influenzae, and Pseudomonas aeruginosa isolates from cases of corneal ulcers were tested for in vitro susceptibility against ceftobiprole, moxifloxacin, gatifloxacin, gentamicin, and vancomycin using a Kirby Bauer method.
Results: :
Ceftobiprole was active against all 15 MRSA strains tested with zones of inhibition ranging from (18 to 38 mm). Moxifloxacin and Gatifloxacin had 8/15 resistant and 10/15 resistant MRSA strains respectively. Gentamicin had 3/15 resistant MRSA organisms. All 15 MRSA strains were sensitive to vancomycin. In addition ceftobiprole was active against all the other isolates.
Conclusions: :
Ceftobiprole is the first of a new class of broad-spectrum anti-MSRA cephalosporins with activity against methicillin-resistant Staphylococcus aureus and gram negative organisms. With increasing concern of resistance among MRSA ocular isolates to currently available antimicrobials ceftobiprole may be a promising new therapeutic alternative.
Keywords: antibiotics/antifungals/antiparasitics • clinical laboratory testing • drug toxicity/drug effects